评估嵌合抗原受体T细胞治疗后出血和血栓风险的荟萃分析:国际血栓与止血学会科学标准化委员会血液肿瘤止血分会的通讯
该系统评价与荟萃分析纳入47项研究共7040例接受CAR T细胞治疗的血液肿瘤患者,评估血栓和出血风险及抗凝抗血小板安全性。随访≤6个月患者每月静脉血栓事件合并发生率为2.4%,任何出血事件为1.9%;随访>6个月分别为0.1%和0.3%。CAR T细胞治疗后血栓和出血风险似乎在输注后最初数月最高。
要点
- 随访≤6个月患者每月静脉血栓事件合并发生率为2.4%(95%CI 1.4%-3.4%;I²=0%)。
- 随访≤6个月患者每月任何出血事件合并发生率为1.9%(95%CI 0.6%-3.1%;I²=78%)。
- CAR T细胞治疗后血栓和出血风险似乎在输注后最初数月最高。
核心结论
- CAR T细胞治疗后血栓和出血风险似乎在输注后最初数月最高。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、EMBASE和Cochrane CENTRAL截至2022年2月,纳入47项研究共7040例接受CAR T细胞治疗的血液肿瘤患者。
- 采用随机效应模型计算合并事件率,并按随访时长、CAR T细胞靶抗原和基础血液肿瘤进行亚组分析。
主要发现
- 研究间异质性高,无法报告血栓和出血事件的总体合并率。
- 随访≤6个月的研究中,每患者月静脉血栓事件合并发生率为2.4%(95%CI 1.4%-3.4%;I²=0%),随访>6个月的研究为0.1%(95%CI 0%-0.1%;I²=0%)。
- 随访≤6个月的研究中,每患者月任何出血事件合并发生率为1.9%(95%CI 0.6%-3.1%;I²=78%),随访>6个月的研究为0.3%(95%CI 0%-0.8%;I²=40%)。
- 按CAR T细胞靶抗原、基础恶性肿瘤和研究主要结局进行的二次分析未显示血栓栓塞、任何出血事件或大出血事件发生率的显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究间异质性高,无法报告血栓和出血事件的总体合并率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chimeric antigen receptor T-cell (CAR T-cell) therapy is increasingly utilized for treatment of hematologic malignancies. Hematologic toxicities including thrombosis and bleeding complications have been reported. Accurate estimates for thrombotic and bleeding outcomes are lacking. OBJECTIVES: We performed a systematic review and meta-analysis in patients who received CAR T-cell therapy for an underlying hematologic malignancy with the objective to: a) assess the thrombosis and bleeding risk associated with CAR T-cell therapy, b) assess the impact of CRS and ICANS on the risks of thrombosis and bleeding, and c) assess the safety of anticoagulant or antiplatelet use in the period following treatment with CAR T-cell therapy. METHODS: We searched MEDLINE, EMBASE, and Cochrane CENTRAL up to February 2022 for studies reporting thrombotic or bleeding outcomes in patients receiving CAR T-cell therapy. Pooled event rates were calculated using a random-effects model. We performed subgroup analyses stratified by follow-up duration, CAR T-cell target antigen, and underlying hematologic malignancy. RESULTS: We included 47 studies with a total of 7040 patients. High heterogeneity between studies precluded reporting of overall pooled rates of thrombotic and bleeding events. In studies with follow-up duration of ≤6 months, the pooled incidence of venous thrombotic events was 2.4% (95% CI, 1.4%-3.4%; I2 = 0%) per patient-month, whereas the rate was 0.1% (95% CI, 0%-0.1%; I2 = 0%) per patient-month for studies with longer follow-up periods (>6 months). The pooled incidences of any bleeding events per patient-month in studies with follow-up duration of ≤6 months and >6 months were 1.9% (95% CI, 0.6%-3.1%; I2 = 78%) and 0.3% (95% CI: 0%-0.8%, I2 = 40%), respectively. Secondary analyses by CAR T-cell target antigen, underlying malignancy, and primary outcome of the studies did not reveal significant differences in the rates of thromboembolism, any bleeding events, or major bleeding events. CONCLUSION: The risk of both thrombosis and bleeding following CAR T-cell therapy appears to be highest in the initial months following infusion.
引用
- Bindal P, Patell R, Chiasakul T, et al. A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. J Thromb Haemost. 2024. PMID: 38574863. doi:10.1016/j.jtha.2024.03.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。